CHAPEL HILL–The National Institutes of Health has awarded the University of North Carolina at Chapel Hill 58.1 million to renew its five-year clinical and translational science (CTSA) award.
Launched in 2006, the CTSA program has enabled innovative research teams to speed discovery and advance science aimed at improving the nation’s health. It supports a consortium of more than 50 academic and medical institutions. The UNC-CH led CTSA program includes an alliance with RTI International and NC Agricultureal and Technical State University and a formal partnership with NC State University.
The award supports a clinical pipeline that takes the latest scientific discoveries in university abs and move them into practice, said UNC-CH Vice Chancellor Terry Magnuson.
The grant provides another five years of funding for the North Carolina Translational and Clinical Sciences (NC TraCS) Institute, recognized as the central entity on the UNC-Chapel Hill campus responsible for the advancement of clinical and translational research. NC TraCS has outreach efforts touching each of North Carolina’s 100 counties.
In the last five years, NC TraCS worked with over 350 practices, 130 community-based organizations, 88 percent of other CTSA hubs, and numerous non-CTSA universities through pilot awards or other initiatives. The Institute led a number of high-impact multi-center clinical trials in HIV, diabetes, obesity, cancer, and pregnancy. It also engaged patients as allies in the research process by developing Join the Conquest, a clinical trials website that includes over 6,000 registered participants and over 200 unique research studies.
